Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UCB Launches Strategic Research Alliance with Weill-Cornell Medical College

Published: Friday, April 04, 2014
Last Updated: Friday, April 04, 2014
Bookmark and Share
Strategic collaboration commences with three discovery programs in areas of high patient need.

UCB has announced that it has launched a major strategic research alliance with Weill-Cornell Medical College that aims to convert scientific discovery into transformative health improvements in areas of high patient need.

This research alliance reflects UCB’s belief that science progresses more rapidly when innovation is fostered by strong partnerships with leading academic partners.

UCB will provide funding for three translational research programs over three years in the areas of bone disorders, metabolic disease and rare genetic variant analysis led respectively by Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill-Cornell Medical College, Dr. Timothy McGraw, Professor of Biochemistry, and Dr. Ronald Crystal, Chairman of Genetic Medicine.

The research programs are aligned with a key strategy of UCB NewMedicines™ to focus on the discovery of medicines targeting pathways with a high level of genetic and human validation.

Ismail Kola, Executive Vice President, UCB & President, New Medicines, UCB said, “No single organization can work alone to translate cutting-edge fundamental scientific research into transformative medicines for people with severe disease. That is why are creating a super network with trusted scientific partners globally, combining knowledge of patient medical need with understanding of disease mechanisms. This strategic research alliance brings together Weill Cornell’s world class academic research with our discovery team with the shared objective of developing medicines that could transform the lives of people with severe diseases.”

“We are thrilled to enter into this strategic alliance with UCB to drive research discoveries made at the bench into the most advanced treatments for patients in the clinic,” Dr. Glimcher said. “UCB has an accomplished track record of developing first-rate treatments and therapies. With complementary expertise and a common mission - to help patients, improve health and save lives - our alliance will demonstrate the power of academic-industry collaboration.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB Announces US and EU Regulatory Filings for Brivaracetam
Major milestone for brivaracetam is latest step towards UCB goal of extending treatment choices for adult epilepsy patients with uncontrolled partial-onset seizures.
Tuesday, January 27, 2015
UCB CEO to Chair IMI Board for a Second Term
Roch Doliveux to spearhead industry’s commitment to world’s biggest public-private partnership in biopharmaceutical research and innovation.
Wednesday, April 02, 2014
UCB CEO to Chair Innovative Medicines Initiative Board
Roch Doliveux confirms industry’s commitment to unique EU public-private partnership.
Monday, March 12, 2012
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
New Skin Cancer Drugs with Surprising Powers
Inserm team synthesizes and developed new drugs for melanoma.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!